Loading... Please wait...

Our Newsletter

BMS-354825 (Dasatinib) | Abl/Src inhibitor

  • BMS-354825 (Dasatinib).jpg
  • BMS-354825 (Dasatinib), 400x400px, png
Catalog #:

Product Description

Dasatinib is an orally-available, aminothiazole-based inhibitor of Abl and Src at IC50 values of 0.6 and 8 nm, respectively. [1] Dasatinib has been shown to be >300-fold more potent than imatinib in cells expressing wild-type Bcr-Abl and in a number of imatinib-resistant mutants at IC50s < 1.7 nM. [2] With the exception of T315I, Dasatinib inhibited cell proliferation of mutants in the range of 0.8 to 11 nM.

Dasatinib's activity against Lck allows for inhibition of T-cell receptor-mediated signal transduction, cellular proflieration, cytokine production, and in vivo T-cell responses. Combination of dasatinib with other immunomodulators such as cyclosporine A or rapamycin results in a synergistic inhibition of T-cell activation. [3]

Technical information:

Chemical Formula:   C22H26ClN7O2S
CAS #:   302962-49-8, 863127-77-9
Molecular Weight:   488.01
Purity:   > 99%
Appearance:   White Crystalline
Chemical Name:   N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Solubility:   Up to 100 mM in DMSO
Synonyms:   BMS-354825, BMS 354825, BMS354825, Sprycel, dasatinibum, Dasatinib

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


1. O'Hare et al., In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005, 65, 4500-4505. Pubmed ID: 15930265
2. Steinberg et al., Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin. Ther. 2007, 29(11), 2289-2308. Pubmed ID: 18158072
3. Schade et al., Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood, 2008, 111, 1366-1377. Pubmed ID: 17962511

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the BMS-354825 (Dasatinib) | Abl/Src inhibitor to your wish list.

You Recently Viewed...